Reneo Pharmaceuticals announces results from STRIDE study of mavodelpar

Reneo Pharmaceuticals announced its pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies (PMM) did not meet its primary efficacy or secondary efficacy endpoint. The primary efficacy endpoint of the trial was the change from baseline in the distance walked during the 12-minute walk test at week 24. The secondary efficacy endpoint was the change from baseline in the PROMIS Short Form Fatigue 13a score. “We are immensely thankful to all the patients, families, and healthcare professionals who participated in the mavodelpar PMM development program,” said Gregory Flesher, President and CEO of Reneo Pharmaceuticals. “Although the results of the STRIDE study were negative, the data generated are vitally important to the scientific community and we will make these data available once the final analyses are complete. Finally, I want to thank all Reneo employees for their dedication and tireless contributions to advancing the science of mitochondrial disease.”